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BACKGROUND: Mitral regurgitation (MR) determines pathophysiology and outcome in advanced heart
failure. The impact of left ventricular assist device (LVAD) placement on clinically significant MR
and its contribution to long-term outcomes has been sparsely evaluated.
METHODS: We evaluated the effect of clinically significant MR on patients implanted in the MOMEN-
TUM 3 trial with either the HeartMate II (HMII) or the HeartMate 3 (HM3) at 2 years. Clinical signifi-
cance was defined as moderate or severe grade MR determined by site-based echocardiograms.
RESULTS: Of 927 patients with LVAD implants without a prior or concomitant mitral valve procedure,
403 (43.5%) had clinically significant MR at baseline. At 1-month of support, residual MR was present
in 6.2% of patients with HM3 and 14.3% of patients with HMII (relative risk = 0.43; 95% CI, 0.22
−0.84; p = 0.01) with a low rate of worsening at 2 years. Residual MR at 1-month post-implant did not
impact 2-year mortality for either the HM3 (hazard ratio [HR],1.41; 95% CI, 0.52−3.89; p = 0.50) or
HMII (HR, 0.91; 95% CI, 0.37−2.26; p = 0.84) LVAD. The presence or absence of baseline MR did
not influence mortality (HM3 HR, 0.86; 95% CI, 0.56−1.33; p = 0.50; HMII HR, 0.81; 95% CI, 0.54
−1.22; p = 0.32), major adverse events or functional capacity. In multivariate analysis, severe baseline
MR (p = 0.001), larger left ventricular dimension (p = 0.002), and implantation with the HMII instead
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CONCLUSIONS: Hemodynamic unloading after LVAD implantation improves clinically significant MR
early, sustainably, and to a greater extent with the HM3 LVAD. Neither baseline nor residual MR influ-
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As heart failure (HF) progresses, geometric alterations in
left ventricular (LV) structure (cavity dilatation, increasing
diameter of the mitral annulus), reduced closing forces on
valvular leaflets, and consequent worsening of ventricular
function lead to a form of secondary mitral regurgitation
(MR). This common finding in advanced HF refractory to
medical therapy is associated with pulmonary hypertension,
right ventricular failure, and a worse prognosis.1 Thus, MR
is encountered frequently in patients with advanced HF
undergoing LV assist device (LVAD) implantation.2
Several questions have been raised regarding MR during
consideration for LVAD implantation. First, it is uncertain
to what degree hemodynamic unloading with an LVAD
ameliorates MR. Second, baseline or residual (post-LVAD)
uncorrected MR may confer adverse prognosis and remains
poorly studied. As a result of these unanswered queries,
clinicians debate the best management of MR at the time of
LVAD surgery with particular emphasis on whether signifi-
cant MR should be corrected concomitantly during the
implant operation.3−6 In registry analyses, concomitant
mitral valve (MV) procedures have been associated with
reduced hospitalizations and better quality of life but not
improved survival.3 Other multicenter studies have pointed
to a survival benefit in those with uncorrected severe MR at
baseline.4 However, single-center studies have demon-
strated that post-LVAD implantation residual MR may
adversely impact hemodynamics and right ventricular func-
tion, whereas others have suggested resolution of severe
MR in most cases after LVAD implantation.5,6 Whether
axial or centrifugal continuous-flow LVADs affect MR
similarly or differentially is unknown.
This post hoc analysis of the MOMENTUM 3 pivotal
trial (clinicaltrials.gov; grant no. NCT02224755), which
randomized patients with advanced HF refractory to medi-
cal therapy to either the fully magnetically-levitated centrif-
ugal-flow LVAD (HeartMate 3) or the axial-flow pump
(HeartMate II), studied the prevalence, resolution, and out-
comes of patients with and without uncorrected clinically
significant MR at the time of LVAD implantation. We fur-
ther sought to identify pre-implant markers for persistent
clinically significant MR following LVAD implantation.
Methods
MOMENTUM 3 trial design
The MOMENTUM 3 trial was a multicenter, 1:1 randomized, piv-
otal study comparing the treatment efficacy of the HeartMate 3
(HM3) LVAD with the HeartMate II (HMII) LVAD in patients
with advanced-stage HF (Abbott, Abbott Park, IL).7 Sixty-nine
U.S. sites enrolled a total of 1,028 patients, and 8 patients were
withdrawn before the implant, leaving 1,020 patients who under-
went implant with their assigned device. Details regarding the
study design and the 2-year primary results from the full study
cohort were published.7−9 The study protocol was approved by
each institutional review board, and written informed consent was
obtained from all patients or their authorized representatives. The
trial was sponsored by Abbott.
Evaluation of MR
In the MOMENTUM 3 trial, data regarding MR was collected from
echocardiograms performed at each site. Qualitative assessment of
MR severity (e.g., none, mild, moderate, severe) was collected from
site-based echocardiogram reports. Data from baseline (pre-implant)
and the 1-, 3-, 6-, 12-, and 24-month post-implant visits were used
for this analysis. Clinically significant MR was defined as either
moderate or severe MR. For this analysis, patients with moderate or
severe baseline MR were combined as the clinical outcomes post-
LVAD implantation were noted to be similar between these patients
(Figure S1). Residual MR refers to the presence of clinically signifi-
cant MR after LVAD implantation.
Analysis cohort
The patient cohort for this analysis is shown in Figure 1. Of the
1,020 patients who underwent LVAD implant in the MOMEN-
TUM 3 trial, 4 patients did not have an echocardiographic assess-
ment of the MV performed at baseline and were excluded from
the analysis. An additional 89 patients had a prior or concurrent
MV repair or replacement and were also excluded. A total of 927
patients were included in the final analysis cohort. The post-
implant completion rates of MV echocardiographic assessment
are shown in Table S1. Of patients on LVAD support, a small per-
centage were missing echocardiogram evaluations at each time
point (< 9%), and rates were similar between those with and with-
out significant baseline MR.
End-points
Within each treatment arm, clinical outcomes were compared
between patients with and without significant baseline MR. The fre-
quency of significant residual MR at 1-month was evaluated. The
primary composite end-point of the MOMENTUM 3 trial was sur-
vival free of disabling stroke (defined by a Modified Rankin score >
3, in which scores range from 0 to 6, with higher scores indicating
more severe disability, including death) or reoperation to remove or
replace a malfunctioning device at 2 years. Other end-points include
overall survival, adverse events, readmissions, New York Heart
Association classification, and the 6-minute walk test. To evaluate
the impact of residual MR on outcomes, we performed a landmark
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analysis to compare survival in patients with and without clinically
significant MR at 1-month post-implant.
Statistical analysis
Continuous variables are described as median and interquartile or
mean § standard deviation. Categorical variables are described as
counts and percentages. Univariate comparisons of categorical
variables were performed with the Wilcoxon’s rank sum test. Uni-
variate comparisons of categorical variables were performed with
the chi-square test or Fisher’s exact test as appropriate. The
Kaplan−Meier method and log-rank test were used for time-to-
event analyses. Survival estimates are presented with 95% CIs.
Hazard ratio (HR) was calculated using Cox proportional hazards
modeling. Adverse event rates are shown as events-per-patient-
year (EPPY), and event rates were compared between groups
using Poisson regression. Rate differences are described as relative
risk (RR) and 95% CI. Longitudinal changes in functional status
were analyzed by linear mixed-effects modeling.
Multivariate logistic regression was performed to identify inde-
pendent predictors of residual MR in patients with clinically sig-
nificant baseline MR. The outcome of interest for the regression
model was the presence of significant residual MR between 1 and
6 months post-implant. First, a set of univariate comparisons of
baseline variables listed in Table 1 was performed to screen for
potential covariates. Covariates identified in the univariate analy-
ses with p < 0.10 were entered using stepwise selection into a mul-
tivariate logistic regression model (p entry criteria = 0.15 and p
stay criteria = 0.10). The odds ratio (OR) for each covariate in the
model is presented with 95% CI.
All reported p values are 2-tailed, and p values < 0.05 are con-
sidered statistically significant. Statistical analyses were per-
formed with SAS software, version 9.4 (SAS Institute, Cary, NC).
Results
Baseline characteristics
Of the 927 patients, 403 (43.5%) had significant baseline
MR (Figure 1). Baseline characteristics of patients grouped
by pre-implant MR severity are shown in Table 1. Approxi-
mately 50% of the patients in each group were implanted
with the HM3 LVAD. Patients with significant baseline
MR were less likely to have an ischemic etiology of HF
compared with patients without MR (39.5% vs 48.5%;
p = 0.006). They also had higher pulmonary capillary
wedge pressure (24 vs 22 mm Hg; p < 0.001), mean pulmo-
nary artery pressure (36 vs 33 mm Hg; p < 0.001), and pul-
monary vascular resistance (3.0 vs 2.7 wood units;
p = 0.02). Significant baseline MR was also associated with
a worse ejection fraction (15% vs 19%; p = 0.01) and larger
LV end-diastolic dimension (70 vs 66 mm; p < 0.001).
Improvement in MR with LVAD support
At baseline, 42.7% of patients with HM3 and 44.2% of
patients with HMII had clinically significant MR
(Figure 2A). After 1 month of LVAD support, the overall
rates of significant MR improved with both pumps to 4.5%
for patients with HM3 and 7.4% for patients with HMII.
Rates of residual MR remained low through the remainder
of the 2-year follow-up. Of the patients with significant
baseline MR, only 6.2% of patients with HM3 compared
with 14.3% of patients with HMII had significant residual
Figure 1 Patient cohort. LVAD, left ventricular assist device; HM3, HeartMate 3; HMII, HeartMate II; MR, mitral regurgitation.
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MR at the 1-month visit (RR, 0.43; 95% CI, 0.22−0.84;
p = 0.01) (Figure 2B). Median pump speeds and flows did
not differ based on the presence of significant baseline MR
or residual MR for either pump (Table S2).
Impact of significant baseline MR on outcomes
Primary composite end-point
Kaplan−Meier estimates of the primary composite end-
point are shown in Figure 3A. There were no differences in
the time to death, disabling stroke, or reoperation in patients
with vs without significant baseline MR for both HM3 (HR,
0.80; 95% CI, 0.54−1.20; p = 0.29) and HMII (HR, 0.79;
95% CI, 0.58−1.09; p = 0.15). In addition, the presence or
absence of significant baseline MR did not alter the superi-
ority of HM3 vs HMII with fewer patients with HM3 failing
the primary end-point (significant MR group: HR, 0.59;
95% CI, 0.39−0.88; p = 0.009; no significant MR group:
HR, 0.57; 95% CI, 0.41−0.78; p < 0.001).
Survival and competing outcomes
Kaplan−Meier estimates of overall survival are shown in
Figure 3B. There were no mortality differences in patients
with vs without significant baseline MR for the HM3 (18.1%
vs 21.5%; HR, 0.86; 95% CI, 0.56−1.33; p = 0.50) and HMII
arms (19.9% vs 26.3%; HR, 0.81; 95% CI, 0.54−1.22;
p = 0.32). The competing outcomes through 2 years are
shown in Figure S2. In addition to mortality, transplantation
rates were also similar, regardless of baseline MR severity.
Adverse events and readmissions
Adverse event rates in EPPY are shown in Figure 4 for
patients with HM3 and HMII. When comparing rates
between patients with and without significant baseline MR,
there were no significant differences for hemocompatibil-
ity-related adverse events, sepsis, right HF, or cardiac
arrhythmias. Rates for all-cause readmissions were also
similar for patients with and without significant baseline
MR.
Functional status
Longitudinal changes in New York Heart Association
classification and the 6-minute walk test are shown in
Figure S3. Significant improvements from baseline
occurred with both pumps and were sustained throughout
the 2 years. There were no differences in functional sta-
tus between patients with and without significant baseline
MR.
Impact of residual MR on outcomes
Landmark analysis of overall survival and competing
outcomes
A landmark analysis of survival between patients with and
without residual MR at 1-month post-implant is shown in
Figure 5. This time point was chosen because maximal
reduction in MR severity was noted at this early follow-up
period. In patients with HM3, 2-year mortality was 22.3%




No significant baseline MR
(n = 524) p-valuea
HM3 pump 197 (48.9%) 264 (50.4%) 0.65
Age, years 63 (53−69) 62 (52−68) 0.11
Male 314 (77.9%) 440 (84.0%) 0.02
Caucasian 265 (65.8%) 375 (71.6%) 0.06
Destination therapy 237 (58.8%) 326 (62.2%) 0.29
Ischemic heart failure 159 (39.5%) 254 (48.5%) 0.006
INTERMACS profile 1-2 139 (34.6%) 158 (30.3%) 0.17
BMI, kg/m2 27 (24−31) 29 (25−33) <0.001
MAP, mm Hg 77 (71−84) 79 (73−86) 0.01
PCWP, mm Hg 24 (18−30) 22 (16−28) <0.001
Mean PAP, mm Hg 36 (30−42) 33 (26−40) <0.001
RAP, mm Hg 10 (6−15) 9 (5−14) 0.008
PAPI 2.6 (1.8−4.3) 2.8 (1.8−4.6) 0.20
PVR, wood units 3.0 (2.0−4.1) 2.7 (1.8−4.0) 0.02
Cardiac index, liter/min/m2 1.82 (1.55−2.20) 1.94 (1.62−2.26) 0.02
LVEF (%) 15 (15−20) 19 (15−20) 0.01
LVEDD, mm 70 (64−77) 66 (61−73) <0.001
LVESD, mm 65 (58−71) 60 (54−67) <0.001
Abbreviations: BMI, body mass index; HM3, HeartMate 3; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic dimension; MAP, mean arterial pressure; MR, mitral regurgitation; PAP, pulmonary artery pressure; PAPI, pulmonary
artery pulsatility index [(systolic PAP − diastolic PAP)/RAP]; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right
atrial pressure.
aWilcoxon’s rank sum test for continuous variables. Fisher’s exact test or chi-square test for categorical variables as appropriate.
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for those with residual MR compared with 17.5% for those
with no residual MR (HR, 1.41; 95% CI, 0.52−3.89;
p = 0.50). In HMII patients, survival was 17.3% vs 21.6%,
respectively, (HR, 0.91; 95% CI, 0.37−2.26; p = 0.84).
Residual MR at 1-month post-implant did not significantly
alter long-term survival with either pump type. Competing
outcomes for patients with and without residual MR at 1-
month post-implant are shown in Figure S4.
Figure 2 Significant MR over time in (A) all patients and (B) patients with significant baseline MR. CI, confidence interval; HM3,
HeartMate 3; HMII, HeartMate II; MR, mitral regurgitation.
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Readmissions
All-cause readmission rates in patients with vs without
residual MR at 1-month post-implant are shown in Table
S3. The readmission rates were 2.28 EPPY in patients with
residual MR vs 2.37 EPPY in patients without residual MR
and did not differ significantly (RR, 0.96; 95% CI, 0.82
−1.14; p = 0.66).
Aortic insufficiency
Post-implant rates of aortic insufficiency (AI) are shown in
Table S4. The occurrence of moderate or severe AI with
either pump was low throughout the study follow-up (<7%
at each visit). Although the total number of patients
experiencing dysfunction in both valves was small, patients
with HM3 with residual MR had a higher rate of AI than
those without residual MR (25.0% vs 2.4% at 24 months;
p = 0.002).
Predictors of persistent significant MR post-
implant
A portion of patients with significant baseline MR contin-
ued to experience significant MR after LVAD implantation.
To identify predictors of persistent significant MR post-
implant, we performed univariate comparisons of all the
baseline variables listed in Table 1. The covariates identi-
fied by univariate analyses with p < 0.10 were entered into
the multivariate logistic regression model using stepwise
selection (Table 2). Severe baseline MR (OR, 2.30; 95%
CI, 1.38−3.84; p = 0.001) and larger LV end-diastolic
dimension (OR, 1.49; 95% CI, 1.15−1.92 per + 10 mm;
Figure 3 Impact of significant baseline MR on the (A) primary end-point and (B) overall survival in the HM3 and HMII arms. The pri-
mary composite end-point is survival free of disabling stroke (defined by a Modified Rankin score > 3, in which scores range from 0 to 6,
with higher scores indicating more severe disability including death) or reoperation to remove or replace a malfunctioning device at 2 years.
HRs are presented for significant baseline MR vs no significant baseline MR. CI, confidence interval; HM3, HeartMate 3; HMII, HeartMate
II; HR, hazard ratio; MR, mitral regurgitation.
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p = 0.002) were independently associated with an increased
likelihood of persistent MR post-implant. In addition, treat-
ment with HM3 vs HMII decreased the likelihood of
experiencing persistent MR (OR, 0.60; 95% CI, 0.36−1.01;
p = 0.05).
Discussion
The principal finding of our study demonstrates that nearly
50% of all LVAD implants are associated with significant
MR at baseline, and hemodynamic unloading with an
LVAD reduces the severity of uncorrected MR to a clini-
cally insignificant degree within 1 month, a finding that is
sustained over the 2-year follow-up period. We also note
that the magnetically-levitated centrifugal-flow HM3 pump
is associated with a greater reduction in the severity of MR
than the axial-flow HMII LVAD. Importantly, neither the
presence of clinically significant baseline MR nor residual
MR at 1-month is associated with adverse long-term out-
comes after LVAD implantation.
The presence of significant MR in advanced HF as a
therapeutic target is disputed.10 Surgical MV repair or
replacement for secondary MR has not been shown to
improve survival in HF. However, 2 separate studies using
transcatheter MV repair have reported distinctive results. In
1 study, the use of the MitraClip (Abbott) in patients with
severe MR after maximizing disease-modifying medical
therapy has been shown to lower mortality and HF hospital-
izations compared with medical therapy alone.11 In con-
trast, another study that enrolled patients with severe MR
Figure 4 Impact of significant baseline MR on adverse event and readmission rates in the HM3 and HMII arms. RRs are presented for
significant baseline MR vs no significant baseline MR. The RR of an adverse event favors no significant baseline MR when the lower
boundary of the 95% CI is >1.0. When the 95% CI spans the line of unity, there is no significant difference between those with and without
significant baseline MR. EPPY, events-per-patient-year; HM3, HeartMate 3; HMII, HeartMate II; MR, mitral regurgitation; RR, relative
risk; RVAD, right ventricular assist device.
Figure 5 Impact of residual MR at 1-month post-implant on overall survival in the HM3 and HMII arms. HRs are presented for residual
MR vs no residual MR. HR, hazard ratio; HM3, HeartMate 3; HMII, HeartMate II; MR, mitral regurgitation.
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and more advanced LV dilatation failed to demonstrate the
benefits of the MitraClip out to 2 years.12 These findings
have led to a vigorous debate over how these 2 trials resulted
in such markedly disparate outcomes. The notion that MR
proportionate to the degree of ventricular dilatation may be
best served by a therapy that targets the ventricle rather than
the valve has been proposed.13,14 The 2-year mortality in
such patients irrespective of treatment of the MV is 34% and
mimics the survival seen in an advanced HF population.12
Our data suggest that LVAD implantation is associated with
a rapid and marked improvement in the severity of MR with
a 2-year mortality rate (»20%) that is significantly lower
even when compared with interventional studies of percuta-
neous MR repair. Whether patients deemed unsuitable for
percutaneous MV repair should be evaluated for potential
LVAD consideration or at least followed closely at advanced
HF programs is now an open question.
Combining valve surgery with LVAD implantation
must be balanced with the trend toward early mortality in
patients undergoing concomitant procedures.15 The
results of our analysis may inform the decision to not
mandatorily treat MV dysfunction during LVAD implan-
tation for 2 reasons. First, the effectiveness of LVAD
implantation alone in ameliorating clinically significant
MR is robust and rapid. Second and more importantly,
residual MR after LVAD implantation does not confer a
late adverse outcome, either on survival, all-cause hospi-
talizations, or transplantation rates. Although this inter-
pretation is reasonable, caution is advised as the
exclusion of 4.6% (47 of 1,020) of trial patients with con-
comitant MV surgery may have confounded results. How-
ever, we believe that this proportion of patients was likely
too small to have materially altered the observations in
the larger trial dataset.
The HM3 LVAD demonstrated a lower rate of residual
MR at 1 month when compared with the HMII pump.
Although direct comparisons to the effectiveness of unload-
ing of these 2 pumps are unavailable, studies with other
hydrodynamic-based centrifugal-flow pumps have suggested
that the axial-flow LVAD achieves greater unloading.16 Our
observations suggest that the unique characteristics of the
magnetically-levitated HM3 pump, which include intrinsic
pulsatility, may facilitate a reduction in MR by improved
systolic leaflet coaptation. The mechanism behind this
may be related to MR characterized by restriction of the
posterior leaflet, in which excessive intracavity LV systolic
pressure reduction exaggerates MR.17 An observational
retrospective analysis of patients predominantly treated
with the HMII axial-flow pump had demonstrated a trend
toward residual MR when there was a greater posterior
displacement of the mitral coaptation point.5 In our analy-
sis, we were unable to establish the reasons for reduced
residual MR with the HM3 LVAD because data collection
did not include MV morphology, and simultaneous assess-
ment of LV contractility, LVAD speed, systemic circula-
tory impedance, and LV end-diastolic volume.
One hypothesis-generating finding in our analysis
relates to the association of residual MR with AI. We
noted that the likelihood of AI rose appreciably when
residual MR was present. Whether this was related to
intentional LVAD speed reduction to ensure aortic leaflet
mobility or MR resulting from increased ventricular load-
ing because of AI cannot be determined by our analysis
and will require another mechanistic study. These obser-
vations illustrate the difficulty and complexity in under-
standing the pathophysiology of MV dysfunction in
advanced HF.
In addition to previously discussed limitations, we note
that a small portion of patients had missing post-implant
echocardiograms at each study visit; however, these rates
were similar across groups and unlikely to have materially
influenced the observed outcomes. The evaluation of MR
and its severity was also qualitatively determined by each
site. Ideally, a core lab could have provided more consistent
quantitative data; however, quantification of secondary MR
is challenging even within clinical trials because of
dynamic loading conditions.18 In a trial of percutaneous
MV repair, 34% of patients reduced their degree of MR
from severe to moderate within 1 month without interven-
tion.11 In our analysis, we chose to include moderate and




No persistent MR post-implant
(n = 299) p-valuea
HM3 34 (39.1%) 156 (52.2%) 0.03
Age, years 62 (50−67) 63 (53−70) 0.04
Ischemic heart failure 26 (29.9%) 124 (41.4%) 0.05
Severe MR at baseline 49 (56.3%) 104 (34.8%) <0.001
LVEDD, mm 74 (67−81) 69 (64−76) <0.001
Multivariate logistic regression OR (95% CI) p-valueb
Severe vs moderate baseline MR 2.30 (1.38−3.84) 0.001
LVEDD, +10 mm 1.49 (1.15−1.92) 0.002
HeartMate 3 vs HeartMate II 0.60 (0.36−1.01) 0.05
HM3, HeartMate 3; LVEDD, left ventricular end-diastolic dimension; MR, mitral regurgitation; OR, odds ratio.
aWilcoxon’s rank sum test for continuous variables. Fisher’s exact test or chi-square test for categorical variables, as appropriate.
bStepwise selection with p-value entry criteria = 0.15 and p-value stay criteria = 0.10.
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severe MR together because of their known dynamic nature.
This approach is further supported by our sub-analysis, sep-
arating moderate and severe MR (Figure S1), which showed
no significant differences in primary or secondary outcomes
post-LVAD between these categories. We also acknowl-
edge that this is a post hoc analysis, and the sample size of
patients with residual MR after LVAD implantation is small
(as a result of the effectiveness of LVAD associated unload-
ing). The small sample size of residual MR limits power
and hence the ability of this analysis to appreciate any
impact of this entity on measures of morbidity, particularly
on sub-categories of hospitalization (e.g., heart failure-
related events alone), time to transplantation, functional
capacity and quality of life. Future analyses with larger
cohorts can elucidate the potential impact of residual MR
on adverse events and identify patients that should undergo
surgical correction of MR for specific clinical indications.
Conclusions
Hemodynamic unloading after LVAD implantation improves
clinically significant MR early, sustainably, and to a greater
extent with the HM3 LVAD. Neither uncorrected baseline
nor residual MR influence outcomes after LVAD implanta-
tion. These findings may call into question the need to surgi-
cally address clinically significant MR at the time of LVAD
implantation.
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